Evidence map›Paper›PMID 21511017›Full record

ArticleInternational journal of pharmaceutics2011

Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles.

Meredith R Clark, Hyder A Aliyar, Chang-won Lee, Julie I Jay, Kavita M Gupta, Karen M Watson, Russell J Stewart, Robert W Buckheit, Patrick F Kiser

Abstract read
In one paragraph

Article in International journal of pharmaceutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Advances in HIV microbicide development.Future medicinal chemistry · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Meredith R ClarkDepartment of Bioengineering, University of Utah, Biopolymers Research Building, 20 South 2030 East, Salt Lake City, UT 84112, United States.
Hyder A Aliyar
Chang-won Lee
Julie I Jay
Kavita M Gupta
Karen M Watson
Russell J Stewart
Robert W Buckheit
Patrick F Kiser
University of Utah · USImQuest BioSciences (United States) · US

Funding

Bioresponsive Microbicides for AIDS PreventionR21AI062445 · NIAID · UNIVERSITY OF UTAH · PI KISER, PATRICK FRANKLIN · 2004 to 2005
$430k
Development of a Novel Semen-Activated Prodrug as an Anti-HIV MicrobicideR21AI079772 · NIAID · IMQUEST BIOSCIENCES · PI BUCKHEIT, ROBERT WALTER · 2009 to 2010
$391k
NIAID NIH HHS 1 R21 AI062445-01NIAID NIH HHS 5R21AI079772-02NIAID NIH HHS R21 AI062445NIAID NIH HHS R21 AI079772
6 · The paper itself

Abstract

This paper describes the design, construction and characterization of the first anti-HIV drug delivery system that is triggered to release its contents in the presence of human semen. Microgel particles were synthesized with a crosslinker containing a peptide substrate for the seminal serine protease prostate specific antigen (PSA) and were loaded with the HIV-1 entry inhibitor sodium poly(styrene-4-sulfonate) (pSS). The particles were composed of N-2-hydroxyproplymethacrylamide and bis-methacrylamide functionalized peptides based on the PSA substrates GISSFYSSK and GISSQYSSK. Exposure to human seminal plasma (HSP) degraded the microgel network and triggered the release of the entrapped antiviral polymer. Particles with the crosslinker composed of the substrate GISSFYSSK showed 17 times faster degradation in seminal plasma than that of the crosslinker composed of GISSQYSSK. The microgel particles containing 1 mol% GISSFYSSK peptide crosslinker showed complete degradation in 30 h in the presence of HSP at 37°C and pSS released from the microgels within 30 min reached a concentration of 10 μg/mL, equivalent to the published IC(90) for pSS. The released pSS inactivated HIV-1 in the presence of HSP. The solid phase synthesis of the crosslinkers, preparation of the particles by inverse microemulsion polymerization, HSP-triggered release of pSS and inactivation of HIV-1 studies are described.

Indexed as

Drug Delivery SystemsCross-Linking ReagentsDrug CarriersDrug CompoundingExcipientsFluorescein-5-isothiocyanateGelsHeLa CellsHIV-1HIV Fusion InhibitorsHIV InfectionsHumansMaleParticle SizePeptidesPolystyrenesCross-Linking ReagentsDrug CarriersExcipientsFluorescein-5-isothiocyanateGelsHIV Fusion InhibitorsPeptidesPolystyrenespolystyrene sulfonic acidProstate-Specific Antigen

Identifiers

PMID21511017
PMCPMC3109121
OpenAlexW2102526979

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.